SOURCE: Active Biotech

June 07, 2007 02:06 ET

TEVA AND ACTIVE BIOTECH TO INITIATE PIVOTAL PHASE III TRIAL PROGRAM OF ORAL LAQUINIMOD FOR RELAPSING MULTIPLE SCLEROSIS

LUND, SWEDEN--(Marketwire - June 7, 2007) - Jerusalem, Israel and Lund, Sweden, June 7, 2007 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Active Biotech AB (OMX NORDIC: ACTI) today announced that the companies are initiating a clinical Phase III program for laquinimod, a novel once-daily, orally administered immunomodulatory compound for the treatment of relapsing multiple sclerosis (RMS). The studies will now begin following the successful conclusion of a second phase II study and the outcome of discussions with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMEA).

Please read the complete press release in the attached file below.


Contacts:

Teva:                                    Active Biotech:
Dan Suesskind                            Sven Andréasson
Chief Financial Officer                  President & CEO
Teva Pharmaceutical Industries Ltd.      +46 46 19 20 49

+ 972 2 589 28 40

George Barrett                           Tomas Leanderson
President and CEO                        Chief Scientific Officer
Teva North America                       +46 46 19 20 95
+1 215 591 30 30

Liraz Kalif / Kevin Mannix               Cecilia Hofvander
Teva Investor Relations                  Manager Corporate Communication
+972 3 926 72 81 / +1 215 591 89 12      +46 46 19 11 22


Teva and Active Biotech to Initiate Pivotal Phase III Trials of Laquinimod for MS -- http://hugin.info/1002/R/1131616/211464.pdf



Copyright © Hugin ASA 2007. All rights reserved.

Contact Information